Searched over 200M research papers
10 papers analyzed
These studies suggest that lisinopril can reduce kidney damage and improve kidney function in various conditions, potentially making some kidney damage reversible.
20 papers analyzed
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used to manage hypertension and heart failure. However, its impact on kidney function, particularly whether it can reverse kidney damage, is a critical area of research. This article synthesizes findings from multiple studies to address the question of whether kidney damage induced by Lisinopril is reversible.
Research indicates that Lisinopril can mitigate acute kidney injury (AKI) induced by nephrotoxic agents. In a study involving male Wistar rats, Lisinopril was shown to reverse the effects of doxorubicin-induced AKI. The treatment reduced serum creatinine and blood urea nitrogen (BUN) levels, decreased kidney injury markers, and improved antioxidant capacity in kidney tissues. This suggests that Lisinopril has a protective effect against acute kidney damage.
In patients with diabetic nephropathy, Lisinopril has been shown to slow the progression of kidney damage. A long-term study comparing Lisinopril with Atenolol found that both drugs effectively reduced the decline in kidney function. However, Lisinopril was more effective in reducing urinary albumin excretion, a marker of kidney damage . This indicates that while Lisinopril may not completely reverse kidney damage, it can significantly slow its progression.
In hypertensive renal transplant recipients, Lisinopril was compared with Nifedipine over a two-year period. The study found that while both drugs were effective in managing hypertension, Nifedipine was more effective in improving renal graft function. Lisinopril did not show a significant improvement in glomerular filtration rates (GFR) compared to Nifedipine. This suggests that Lisinopril may not be as effective in reversing kidney damage in transplant patients.
Lisinopril has also been studied for its effects on adriamycin-induced nephropathy. The drug was found to reduce proteinuria, lower systolic blood pressure, and decrease morphologic kidney lesions. Additionally, Lisinopril increased renalase expression in kidney tissues, which is associated with reduced kidney damage. These findings suggest that Lisinopril can attenuate kidney damage induced by nephrotoxic agents.
In a model of hypertension-induced kidney damage, Lisinopril was shown to reverse oxidative stress markers and improve renal function. The treatment normalized serum creatinine levels and reduced oxidative stress markers in kidney tissues, indicating a reversal of hypertensive kidney damage. This supports the potential of Lisinopril to reverse certain types of kidney damage.
In patients with chronic allograft nephropathy, Lisinopril was found to reduce proteinuria and improve markers of kidney function. The study concluded that Lisinopril did not adversely affect the rate of decline in renal graft function and suggested a relative preservation of graft function. This indicates that Lisinopril can be beneficial in managing chronic kidney conditions without worsening kidney function.
The evidence suggests that Lisinopril has a protective effect against various forms of kidney damage, including acute kidney injury, diabetic nephropathy, and hypertensive kidney damage. While it may not completely reverse kidney damage, Lisinopril can significantly slow its progression and improve certain markers of kidney function. Further research is needed to fully understand the long-term effects of Lisinopril on kidney health.
Most relevant research papers on this topic